{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:56:11Z","timestamp":1785488171137,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejogrb.2020.10.052","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T21:27:01Z","timestamp":1604006821000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Does symptom severity predict response to low-dose onabotulinumtoxinA for the treatment of urgency urinary incontinence?"],"prefix":"10.1016","volume":"256","author":[{"given":"Hector M.","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-1744","authenticated-orcid":false,"given":"Joy E.","family":"Wheat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Gehrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejogrb.2020.10.052_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ejogrb.2020.10.052_bib0010","series-title":"Epidemiology and social impact of urinary and fecal incontinence. Urogynecology and reconstructive pelvic surgery","first-page":"96","author":"Sung","year":"2014"},{"key":"10.1016\/j.ejogrb.2020.10.052_bib0015","series-title":"Clinical updates in women\u2019s health care","author":"Al","year":"2020"},{"issue":"5","key":"10.1016\/j.ejogrb.2020.10.052_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00192-018-3778-0","article-title":"Association of baseline severity of lower urinary tract symptoms with the success conservative therapy for urinary incontinence in women","volume":"30","author":"Obloza","year":"2019","journal-title":"Int Urogynecol J"},{"issue":"2","key":"10.1016\/j.ejogrb.2020.10.052_bib0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00192-018-3640-4","article-title":"Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?","volume":"30","author":"Goldman","year":"2019","journal-title":"Int Urogynecol J"},{"issue":"2","key":"10.1016\/j.ejogrb.2020.10.052_bib0030","article-title":"Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB","volume":"11","author":"Wang","year":"2019","journal-title":"Luts Low Urin Tract Symptoms"},{"issue":"3","key":"10.1016\/j.ejogrb.2020.10.052_bib0035","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"BOTULINUM-A toxin for treating DETRUSOR HYPERREFLEXIA IN SPINAL CORD INJURED PATIENTS: a new alternative to anticholinergic drugs? Preliminary Results","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ejogrb.2020.10.052_bib0040","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1097\/01.ju.0000143889.00681.3f","article-title":"The effect of BOTULINUM-A toxin on patients with severe urge Urinary Incontinence","volume":"172","author":"Flynn","year":"2004","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ejogrb.2020.10.052_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum a injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ejogrb.2020.10.052_bib0050","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum Toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, Double-Blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ejogrb.2020.10.052_bib0055","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum a toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ejogrb.2020.10.052_bib0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","article-title":"Experience with 100 cases treated with Botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics","volume":"176","author":"Schmid","year":"2006","journal-title":"J Urol"},{"issue":"19","key":"10.1016\/j.ejogrb.2020.10.052_bib0065","first-page":"376","article-title":"Anticholinergic therapy vs. OnabotulinumtoxinA for urgency urinary incontinence","author":"Visco","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejogrb.2020.10.052_bib0070","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of OnabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ejogrb.2020.10.052_bib0075","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ejogrb.2020.10.052_bib0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study)","volume":"62","author":"Tincello","year":"2012","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejogrb.2020.10.052_bib0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ejogrb.2020.10.052_bib0090","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: resuts of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ejogrb.2020.10.052_bib0095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo\u2010controlled dose\u2010finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodyn"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211520306898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211520306898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:50:18Z","timestamp":1759557018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211520306898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"alternative-id":["S0301211520306898"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.10.052","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does symptom severity predict response to low-dose onabotulinumtoxinA for the treatment of urgency urinary incontinence?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.10.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}